Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

First Episealer® Talus surgery planned in Belgium

Episurf Medical (Nasdaq: EPIS B) today announces that the first surgery with the ankle implant Episealer® Talus in Belgium has been scheduled. In February 2022, Episurf Medical communicated that reimbursement coverage for Episealer® Talus in Belgium had been obtained. “We have for been offering our Episealer® Knee technology to our Belgian customers for some time, and we are now pleased to also be able to offer our Episealer® Talus technology in the country. The first surgery is always an important milestone”, says Pål Ryfors, CEO Episurf Medical.

eEquity invests in Venture Design – a leading online B2B2C player in furniture

eEquity, a Nordic growth investor focused on digitally enabled businesses, has completed an investment in furniture seller Venture Design. eEquity is the only investor in the financing round encompassing almost EUR 10 million. Venture Design operates as a furniture sales partner with a B2B2C model that incorporates sourcing expertise, professional product captioning and dropshipping delivering directly to end-users. With this partnership, Venture Design will continue their growth journey, aiming to become a leading B2B2C player within home furnishing in Europe.Sweden-based Venture Design,

Company Announcement No. 50, 2022 – Addendum to Nordea Kredits final terms

The following security code has been added to the final terms of fixed rate callable covered mortgage bonds (SDRO):  Callable fixed-rate annuity bond   ISIN code Nom Name Opening Closing Maturity Currency interest date date date rate/Matu rity DK0002054436 3.0% 3.0NDASDRO43 28/04 31/08 01/10 DKK          2043 -2022 -2023 -2043   DK0002054865 3.5% 3.5NDASDRO53 28/04 31/08 01/10 DKK

NOTIFICATION OF MANAGERS’ AND CLOSELY RELATED PARTIES’ TRANSACTIONS WITH DAMPSKIBSSELSKABET NORDEN A/S’ SHARES IN CONNECTION WITH SHARE BUY-BACK PROGRAM

ANNOUNCEMENT NO. 103 - 26 APRIL 2022 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp participates by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in Dampskibsselskabet NORDEN A/S. The market will be informed accordingly – see the attached file and announcement no. 56/2022. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information:Thomas France, Investor Communications Partner, tel.: 3315 0451

BioStock: New DexTech chairman wants to turn up the volume

With positive phase II data in castration-resistant prostate cancer and upcoming studies in multiple myeloma, DexTech is now taking further steps to accelerate development. Joining the company as the new Chairman of the Board, Andreas Segerros is tasked with building a team to fully leverage the platform technology. BioStock spoke to Segerros to find out more about his background and his view of the mission at DexTech.Read the full article at biostock.se:https://www.biostock.se/en/2022/04/new-dextech-chairman-wants-to-turn-up-the-volume/This is a press release from BioStock - Connecting

Capital increase in TORM due to exercise of Restricted Share Units as part of TORM’s incentive program

TORM plc (“TORM”) increases its share capital by 34,189 A-shares (corresponding to a nominal value of USD 341.89) as a result of the exercise of a corresponding number of Restricted Share Units.   The capital increase is carried out without any pre-emption rights for existing shareholders or others. 7,090 new shares have been subscribed for in cash at DKK 43.4 per A-share, the remaining 27,099 of the new shares have been subscribed for in cash at DKK 53.5 per A-share. All with a nominal value of USD 0.01 each.   The new shares are ordinary shares without any special rights and

Invitation to presentation in connection with EQL Pharma's year-end report, fourth quarter, 2021/22

EQL Pharma AB (publ) will publish its year-end report 2021/22, on Friday, May 13[th]. At 10.00 (CET) 13[th] May, the company will give a presentation via video conference. The presentation is aimed at shareholders and potential shareholders. President and CEO Christer Fåhraeus presents and comments on the quarterly report. After the presentation, there is an opportunity to ask questions for those who participate. Use the following link to access the virtual meeting: https://tinyurl.com/3muf2962Date and time May 13[th], 2022, at 10.00 (CET) the presentation starts. Time required for

SmartCraft ASA (SMCRT) - Annual Report 2021

SmartCraft ASA | Annual financial and audit reports  26 April 2022 - SmartCraft ASA today published its Annual Report and Sustainability Report for 2021. The report follows enclosed together with the company’s annual financial statements in European Single Electronic Format (ESEF). The documents are also available on the Company's website. “2021 was SmartCraft’s first year as a listed company, and we delivered well on our clear strategy to continue our organic and M&A driven growth combined with high profitability and strong cash flow,” said CEO of SmartCraft Gustav Line. During

Remedy Entertainment Plc – Correction: Adoption of IFRS and unaudited IFRS comparison figures

Remedy Entertainment Plc | Company Announcement 10.15 a.m. (EEST) 26 April 2022 Remedy Entertainment Plc – Correction: Adoption of IFRS and unaudited IFRS comparison figures Remedy Entertainment yesterday 25.4.2022 published a release titled Adoption of IFRS and unaudited IFRS comparison figures. During the release publishing process, there was a technical problem which caused the English version of the release to lack the Capitalization of Development Costs title row in the tables “Statement of comprehensive income 1 October – 31 December 2021 and 1 January – 31 December 2021” and “

Reminder: Invitation to DNB's first quarter presentation, Thursday, 28 April 2022

DNB will publish its results for the first quarter of 2022 on Thursday, 28 April 2022 at 7.30 CET. 9:30 CET: Presentation CEO Kjerstin Braathen and CFO Ida Lerner present the results at a live streamed press conference. A broadcast will be available on the Investor Relations pages at ir.dnb.no. It will also be possible to physically attend to the presentation at DNB's head office in Bjørvika, Dronning Eufemias gate 30. Please register your attendance in Oslo, at ca@dnb.no. 13:30 CET: Conference call for analysts and investors Call in details: Norway +47 21 56 33 18, UK Wide +44 (

Valio to sell its Russian operations

Valio has completed negotiations on the divestment of its Russian operations. Valio will sell the operations to Velkom Group. The transaction will take place immediately.With the transaction, Valio’s personnel in Russia will transfer to Velkom Group. The parties have decided not to disclose the value of the transaction. With the completed transaction, Valio’s operations in Russia have now ended. The transaction includes Valio’s Russian operations and the processed cheese factory in Ershovo. The Viola® brand processed cheese sold and produced in Russia is also part of the transaction,

ANNOUNCEMENT OF THE NAV OF P CAPITAL PARTNERS IV

Stockholm, 26 April 2022 Today the Net Asset Values of the P Capital Partners IV participation loan debentures is at the close of business on 25 April 2022 EUR 97.40 per each of the series A1 participation loan debentures. The Net Asset Value of P Capital Partners IV participation loan debentures is to be calculated at the close of each quarter and in conjunction with a capital increase or decrease. The Net Asset Value has been set, as a result of P Capital Partners IV increasing its contributed capital by EUR 15.5 million, through the issuance of 161,952 series A1 participation

ANNOUNCEMENT OF THE NAV OF P CAPITAL PARTNERS IV B

Today the Net Asset Values of the P Capital Partners IV B participation loan debentures are being announced. At the close of business on 25 April 2022, the Net Asset Value of the series A1 participation loan debentures amounted to EUR 97.20 each, and the Net Asset Value of the series B participation loan debenture amounted to EUR 972.18 each. The Net Asset Value of P Capital Partners IV B participation loan debentures is to be calculated at the close of each quarter and in conjunction with a capital increase or decrease. The Net Asset Value has been set as a result of P Capital

A faster pace and higher targets in LKAB's transition towards a sustainable future

LKAB is now boosting both the pace and the level of ambition in its plans towards the transition to carbon-dioxide-free sponge iron. A successful exploration programme with dramatically increasing mineral resources means that the plan for future production of sponge iron has been upped to 24.4 million tonnes by 2050. This will enable a reduction in carbon dioxide emissions among global steel industry customers corresponding to nearly all of Sweden's current greenhouse gas emissions."The climate can't wait and demand for the raw material for producing fossil-free steel is already upon us –

BioStock: Ultimovacs protects cancer vaccine technology until 2037

Norwegian biotech Ultimovacs has announced receiving a Notice of Allowance from the U.S. Patent and Trademark Office regarding its universal cancer vaccine UV1 in combination with various classes of checkpoint inhibitors. Once formally granted, the patent will protect Ultimovacs’ technology until at least June 2037.Read the article at biostock.se : https://www.biostock.se/en/2022/04/ultimovacs-protects-cancer-vaccine-technology-until-at-least-2037/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Trelleborg acquires US healthcare & medical company

Trelleborg Group has, through its business area Trelleborg Sealing Solutions, signed an agreement and finalized the acquisition of the US-based company EirMed, LLC. The company specializes in technical precision plastic injection-molded components, which are mainly applied in medical devices, such as those used for in-vitro diagnostics, minimally invasive surgery, and orthopedics.   The company has its head office and manufacturing in Menomonie, Wisconsin, in the US. Sales amounted to approximately SEK 100 M in 2021.   The healthcare & medical market is expected to report stable

UPM Interim Report Q1 2022: Strong performance supported by tight markets

UPM-Kymmene Corporation        Stock Exchange Release (Interim Report)        26 April 2022 at 09:50 EEST UPM Interim Report Q1 2022:Strong performance supported by tight markets Q1 highlights · Sales increased by 12% to EUR 2,507 million (2,234 million in Q1 2021) · Comparable EBIT was in line with last year at EUR 277 million, 11.0% of sales (279 million, 12.5%) · Operating cash flow was EUR 12 million (217 million) · Net debt increased to EUR 837 million (83 million) and net debt to EBITDA ratio was 0.46 (0.06) · Sales prices increased in all business areas and

QUARTERLY REPORT, FIRST QUARTER 2022

  Press release: Stockholm, April 26, 2022, 08.45 CET HIGHLIGHTS OF THE FIRST QUARTER 2022 · Net sales was 114 MSEK compared to the previous year 95 MSEK. Major positive contributors were favourable development of zinc price and produced amount of gold and zinc  · EBITDA was 38 MSEK (14) · EBIT was 15 MSEK (-6) · Cash and cash equivalents were 44 MSEK (26) · Investments were 13 MSEK (8) · The production was about 336 000 (344 000) ounces of silver, 870 (707) ounces of gold, 465 (309) tonnes of lead, and 990 (664) tonnes of zinc in concentrates · The

Carbiotix completes expansion of research and development laboratory

Carbiotix (publ) ("Carbiotix" or "Company") announces today that the Company has completed the expansion of its research and development laboratory in Lund, Sweden. The expansion of a third laboratory will provide us separate laboratories for LinkGut sample analysis, microbial therapeutic research, and prebiotic ingredient development. The laboratory expansion will also provide additional office space that will allow the Company to bring together all personnel based in Lund into one office and laboratory area. The expansion allows Carbiotix to ramp up research and development activities

Mandatory notification of trade

Anooj Unarket, Board member of Otello Corporation ASA, has on behalf of certain related parties, as of 25th April 2022, acquired interests in shares of Otello Corporation ASA. The balance of Anooj Unarket and related parties’ holdings after the transaction totals 27,755,037 shares. Please refer to the attached notification of trading for further details. This information is subject to disclosure requirements in regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act section 5-12.

Realheart to recruit new CFO

Press release 26 April, 2022 Realheart has initiated the process of recruiting a new Chief Financial Officer to take over when current CFO Andreas Hultdin leaves on 31 July.Realheart is a Swedish company headquartered in Västerås, which is developing the world's first artificial four-chamber heart. The company has recently taken several important steps forward, not least in leaving the prototype behind and instead test the clinical version of the Realheart TAH in the animal studies that are about to be initiated. ''As we step by step move closer the clinical trial phase, we see

Interim report January–March 2022 – Pricer AB (publ)

High order intake of 24.4% and net sales growth of 18.6 %   Q1 2022   · Net sales amounted to SEK 465.9 M (392.9) an increase of 18.6 percent compared to the same period last year. · Operating profit amounted to SEK -9.7 M (17.3), which corresponds to an operating margin of -2.1 percent (4.4). · Order intake was 551 MSEK (443), an increase of 24,4 percent compared to the same period last year. · Order backlog amounted to SEK 464 M (550), of which the majority is expected to be delivered in Q2 and Q3 2022. · Profit for the period was SEK -9.5 M (17.7). · Earnings

Genova has entered into new financing agreements of approximately SEK 3,200m

Genova Property Group AB (publ) has entered into new financing agreements with Swedbank AB (publ) for a total of SEK 3,200m, of which SEK 350m consists of a revolving credit facility. The new facilities relate to Genova's existing investment property portfolio and comprise a total of 43 properties. The refinancing also strengthens Genova's liquidity by almost SEK 170m. The new financing agreements will mature in May 2027, with an average maturity of approximately 4 years. The new financing agreements are based on Genova's green framework and can be converted to green financing when

There are no items matching the current filter
There are no more items matching the current filter
Back to top